Literature DB >> 20037181

Long-term prognosis of patients with peripheral arterial disease with or without polyvascular atherosclerotic disease.

Jan-Peter van Kuijk1, Willem-Jan Flu, Gijs M J M Welten, Sanne E Hoeks, Michel Chonchol, Radosav Vidakovic, Hence J M Verhagen, Jeroen J Bax, Don Poldermans.   

Abstract

AIMS: Patients with peripheral atherosclerotic disease often have multiple affected vascular beds (AVB), however, data on long-term follow-up and medical therapy are scarce. We assessed the prevalence and prognostic implications of polyvascular disease on long-term outcome in symptomatic peripheral arterial disease (PAD) patients. METHODS AND
RESULTS: Two thousand nine hundred and thirty-three consecutive patients were screened prior to surgery for concomitant documented cerebrovascular disease and coronary artery disease. The number of AVB was determined. Cardiovascular medication as recommended by guidelines was noted at discharge. Single, two, and three AVB were detected in 1369 (46%), 1249 (43%), and 315 (11%) patients, respectively. During a median follow-up of 6 years, 1398 (48%) patients died, of which 54% secondary to cardiovascular cause. After adjustment for baseline cardiac risk factors and discharge-medication, the presence of 2-AVB or 3-AVB was associated with all-cause mortality (HR 1.3 95% CI 1.2-1.5; HR 1.8 95% CI 1.5-2.2) and cardiovascular mortality (HR 1.5 95% CI 1.2-1.7; HR 2.0 95% CI 1.6-2.5) during long-term follow-up, respectively. Patients with 2- and 3-AVB received extended medical treatment compared with 1-AVB at the time of discharge.
CONCLUSION: Polyvascular atherosclerotic disease in PAD patients is independently associated with an increased risk for all-cause and cardiovascular mortality during long-term follow-up.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20037181     DOI: 10.1093/eurheartj/ehp553

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  14 in total

1.  The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline.

Authors:  Amy M West; Justin D Anderson; Craig H Meyer; Frederick H Epstein; Hongkun Wang; Klaus D Hagspiel; Stuart S Berr; Nancy L Harthun; Joseph M DiMaria; Jennifer R Hunter; John M Christopher; Joshua D Chew; Gabriel B Winberry; Christopher M Kramer
Journal:  Atherosclerosis       Date:  2011-04-16       Impact factor: 5.162

2.  Long-Term Outcomes and Causes of Death in Patients With Renovascular Disease Undergoing Renal Artery Stenting.

Authors:  Eric L Wallace; Ediz Tasan; Bryon S Cook; Richard Charnigo; Ahmed K Abdel-Latif; Khaled M Ziada
Journal:  Angiology       Date:  2015-09-30       Impact factor: 3.619

Review 3.  Successful Peripheral Vascular Intervention in Patients with High-risk Comorbidities or Lesion Characteristics.

Authors:  E Hope Weissler; J Antonio Gutierrez; Manesh R Patel; Rajesh V Swaminathan
Journal:  Curr Cardiol Rep       Date:  2021-03-05       Impact factor: 2.931

4.  Cardiovascular and Limb Events Following Endovascular Revascularization Among Patients ≥65 Years Old: An American College of Cardiology PVI Registry Analysis.

Authors:  E Hope Weissler; Yongfei Wang; Jordan M Gales; Dmitriy N Feldman; Shipra Arya; Eric A Secemsky; Herbert D Aronow; Beau M Hawkins; J Antonio Gutierrez; Manesh R Patel; Jeptha P Curtis; W Schuyler Jones; Rajesh V Swaminathan
Journal:  J Am Heart Assoc       Date:  2022-06-20       Impact factor: 6.106

5.  Assessment of Carotid Artery Stenosis and the Use of Statins.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2015-06-05

6.  Extrarenal atherosclerotic disease blunts renal recovery in patients with renovascular hypertension.

Authors:  Kirandeep K Khangura; Alfonso Eirin; Garvan C Kane; Sanjay Misra; Stephen C Textor; Amir Lerman; Lilach O Lerman
Journal:  J Hypertens       Date:  2014-06       Impact factor: 4.844

7.  Korean Multicenter Registry Study of EPIC Stents for the Treatment of Iliac Artery Disease: K-EPIC Registry.

Authors:  Dae Young Kim; Young Guk Ko; Seung Jun Lee; Chul Min Ahn; Seung Woon Rha; Cheol Ung Choi; Jong Kwan Park; Chang Hwan Yoon; Seung Hyuk Choi; Pil Ki Min; Jang Whan Bae; Jung Kyu Han; Sang Ho Park; Donghoon Choi
Journal:  Korean Circ J       Date:  2021-01-27       Impact factor: 3.243

8.  Cross vascular risk for first and recurrent hospitalised atherothrombosis determined retrospectively from linked data.

Authors:  Tom G Briffa; Lee J Nedkoff; Matthew W Knuiman; Graeme J Hankey; Paul E Norman; Joseph Hung; Peter L Thompson; Siobhan Hickling; Alexandra Bremner; Frank M Sanfilippo
Journal:  BMJ Open       Date:  2013-11-20       Impact factor: 2.692

9.  C-reactive protein, renal function, and cardiovascular outcome in patients with symptomatic peripheral artery disease and preserved left ventricular systolic function.

Authors:  Mislav Vrsalović; Ksenija Vučur; Boris Car; Tomislav Krčmar; Ana Vrsalović Presečki
Journal:  Croat Med J       Date:  2015-08       Impact factor: 1.351

10.  Disease location is associated with survival in patients with peripheral arterial disease.

Authors:  Qian Chen; Carin Y Smith; Kent R Bailey; Paul W Wennberg; Iftikhar J Kullo
Journal:  J Am Heart Assoc       Date:  2013-10-21       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.